News | August 13, 2009

Abbott Expands XIENCE V USA Trial to Enroll Patients into Dual Anti-Platelet Therapy Trial

August 13, 2009 – Abbott today announced the expansion of the company's XIENCE V USA post-approval study designed to evaluate the safety and effectiveness of the company's XIENCE V Everolimus-Eluting Coronary Stent System in a real-world clinical setting out to five years. The expansion allows for more than 2,000 patients from the trial to be eligible to cross over into the landmark Dual Anti-Platelet Therapy (DAPT) Trial, an industry-wide collaboration with medical device and pharmaceutical companies.

"The expansion of the XIENCE V USA trial will enable Abbott to enroll more than 2,000 patients who may be eligible to also participate in the DAPT Trial to help advance the body of scientific knowledge regarding the best duration for patients to take blood-thinning medications after a stent procedure," said Charles Simonton, M.D., FACC, FSCAI, divisional vice president, medical affairs, and chief medical officer, Abbott Vascular. "We anticipate the DAPT Trial results will be instrumental in establishing definitive guidelines."

The first patient was enrolled into the XIENCE V USA expansion by James Hermiller, M.D., director, cardiac catheterization labs, The Care Group at St. Vincent Hospital in Indianapolis, Ind. Dr. Hermiller is a principal investigator of the XIENCE V USA trial, along with Mitch Krucoff, M.D., FACC, FCCP, director, cardiovascular devices unit, Duke Clinical Research Institute in Durham, N.C.

The XIENCE V USA trial expansion allows for an additional 3,000 patients to be enrolled into Abbott's study, which was originally designed to study 5,000 patients in the United States. The primary endpoint of XIENCE V USA is a measure of stent thrombosis every year out to five years, as defined by the Dublin/Academic Research Consortium (ARC). The ARC definition of late stent thrombosis was developed to eliminate variability in the definitions across various drug eluting stent trials.

The DAPT Trial is an independent, large-scale study in size (20,000 or more patients) and scope intended to determine the appropriate duration for dual anti-platelet therapy (the combination of aspirin and a second anti-clotting medication to reduce the risk of blood clots) as well as the safety and effectiveness of DAPT to protect patients from stent thrombosis and major adverse cardiovascular and cerebrovascular events (MACCE) following the implantation of either a drug-eluting or bare metal stent.

The DAPT concept was developed by a consortium of eight companies (four major stent manufacturers, including Abbott, and four manufacturers of anti-platelet medications) who came together to address a FDA request for this post-market study. The Harvard Clinical Research Institute is responsible for the design, conduct and analysis of the overall study.

For more information: www.xiencev.com, www.abbott.com. www.hcri.harvard.edu

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Registry Identifies Early Onset of Heart Failure and Lack of Defibrillators in Asia
News | Heart Failure| August 03, 2017
August 3, 2017 — The Asian Pacific Society of Cardiology (ASPC) held its first-ever late-breaking...
Overlay Init